Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 1 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Pelanserin AI simulator
(@Pelanserin_simulator)
Hub AI
Pelanserin AI simulator
(@Pelanserin_simulator)
Pelanserin
Pelanserin (developmental code name TR-2515) is a serotonin 5-HT2 and α1-adrenergic receptor antagonist which was under development for the treatment of hypertension but was never marketed. Its development was discontinued in 2001.
The pharmacokinetics of pelanserin have been studied. It has a relatively short elimination half-life. The drug's time to peak levels was less than 1 hour and its half-life was 3.8 hours in a single subject in an analytical study.
Pelanserin (3) can be synthesized by a reaction between isatoic anhydride (1) and 1-(3-aminopropyl)-4-phenylpiperazine (2) in the presence of phosgene.
Pelanserin
Pelanserin (developmental code name TR-2515) is a serotonin 5-HT2 and α1-adrenergic receptor antagonist which was under development for the treatment of hypertension but was never marketed. Its development was discontinued in 2001.
The pharmacokinetics of pelanserin have been studied. It has a relatively short elimination half-life. The drug's time to peak levels was less than 1 hour and its half-life was 3.8 hours in a single subject in an analytical study.
Pelanserin (3) can be synthesized by a reaction between isatoic anhydride (1) and 1-(3-aminopropyl)-4-phenylpiperazine (2) in the presence of phosgene.
Recent media
Recent media